FDA has approved Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
